Compare Merck & Co., Inc. (MRK) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Transocean Ltd — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Transocean Ltd trades at $5.75 (market cap $6.43B). The key difference: Merck & Co., Inc. is far larger — about 57× Transocean Ltd's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| MRK | RIG | |
|---|---|---|
Market Cap | $366.28B | $6.43B |
Sector | Health | Technology |
52-Week High | $156.43 | $7.58 |
52-Week Low | $77.60 | $3.08 |
Enterprise Value | $413.04B | $11.04B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Transocean (RIG) trades at $5.76, down 1.54% today, with a bearish technical signal despite recent earnings beat. The company shows improving operational cash flow ($995M in 2026) and secured a $300M contract with ONGC, but faces challenges with negative net income margins (-40.24%) and high debt levels. Analyst sentiment is mixed with 39% buy ratings amid ongoing profitability concerns.
RIG presents a high-risk opportunity with improving contract backlog and cash flow generation potential offset by substantial debt burden and inconsistent earnings performance. Investors should weigh the company's exposure to volatile oil prices against its position in the tightening deepwater drilling market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
